INT144019

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 21
Total Number 21
Disease Relevance 14.93
Pain Relevance 1.26

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Pdgfrb) plasma membrane (Pdgfrb) nucleus (Pdgfrb)
kinase activity (Pdgfrb) lysosome (Pdgfrb) cytoplasm (Pdgfrb)
Anatomy Link Frequency
platelet 1
HGF 1
Pdgfrb (Mus musculus)
Pain Link Frequency Relevance Heat
Kinase C 3 100.00 Very High Very High Very High
Taxol 42 98.24 Very High Very High Very High
fibrosis 102 97.64 Very High Very High Very High
cva 22 93.64 High High
Analgesic 3 91.56 High High
fluoxetine 3 88.76 High High
Serotonin 2 85.32 High High
cytokine 21 85.24 High High
positron emission tomography 49 64.40 Quite High
imagery 15 63.36 Quite High
Disease Link Frequency Relevance Heat
Fibromyalgia 5 99.92 Very High Very High Very High
Lung Cancer 141 99.64 Very High Very High Very High
Cancer 895 99.50 Very High Very High Very High
Gastrointestinal Stromal Tumor 442 99.20 Very High Very High Very High
Myelodysplastic Syndromes 45 99.20 Very High Very High Very High
Carcinoma 32 98.20 Very High Very High Very High
Leukemia 55 97.80 Very High Very High Very High
Pulmonary Fibrosis 68 97.64 Very High Very High Very High
Cervical Cancer 4 96.44 Very High Very High Very High
Chondrosarcoma 23 95.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhibition of PDGFR kinase with imatinib or AG1296 blocks 5-HT-stimulated PDGFRbeta phosphorylation. 5-HTT inhibitors and the Na+/K+-ATPase inhibitor ouabain, but not 5-HT2 and 5-HT1B/1D receptor inhibitors, block PDGFRbeta activation by 5-HT.
Negative_regulation (Inhibition) of PDGFR
1) Confidence 0.58 Published 2007 Journal FASEB J. Section Abstract Doc Link 17504974 Disease Relevance 0.28 Pain Relevance 0.12
Therapy with this inhibitor of several protein-tyrosine kinases, including ABL, PDGFR, KIT and FMS tyrosine kinase, has been proposed.
Negative_regulation (inhibitor) of PDGFR associated with fibromyalgia
2) Confidence 0.43 Published 2007 Journal Intern Emerg Med Section Body Doc Link PMC2780604 Disease Relevance 0.86 Pain Relevance 0.04
Inhibition of PDGFR kinase with imatinib or AG1296 significantly inhibits SMC proliferation and migration induced by 5-HT in vitro.
Negative_regulation (Inhibition) of PDGFR
3) Confidence 0.42 Published 2007 Journal FASEB J. Section Abstract Doc Link 17504974 Disease Relevance 0.20 Pain Relevance 0.12
Thus, there is a growing interest in the development of tumor treatment strategies by blocking PDGF/PDGFR function.
Negative_regulation (blocking) of PDGFR associated with cancer
4) Confidence 0.40 Published 2007 Journal BMC Cancer Section Abstract Doc Link PMC2234427 Disease Relevance 1.00 Pain Relevance 0
Imatinib mesylate inhibits platelet-derived growth factor receptor (PDGFR), and there are evidences that the PDGFR participates in development and progression of cervical cancer.
Negative_regulation (inhibits) of PDGFR in platelet associated with cervical cancer
5) Confidence 0.30 Published 2009 Journal Int. J. Gynecol. Cancer Section Abstract Doc Link 19955950 Disease Relevance 0.30 Pain Relevance 0.03
Imatinib mesylate (Gleevec), an inhibitor of PDGFR tyrosine kinase and c-Abl, has been evaluated in a clinical trial for the treatment of IPF [51].
Negative_regulation (inhibitor) of PDGFR associated with fibrosis
6) Confidence 0.29 Published 2010 Journal Fibrogenesis Tissue Repair Section Body Doc Link PMC2940818 Disease Relevance 0.90 Pain Relevance 0.21
Nilotinib selectively inhibits Bcr-Abl, Kit, and PDGFR tyrosine kinases, but does not significantly affect any of the kinases required for IL-3 signaling, such as JAK2, or a broad variety of other receptor tyrosine kinases or tyrosine kinase oncogenes (Weisberg et al 2005).
Negative_regulation (inhibits) of PDGFR
7) Confidence 0.28 Published 2008 Journal OncoTargets and therapy Section Body Doc Link PMC2994207 Disease Relevance 1.25 Pain Relevance 0
Imatinib was initially designed as a PDGFR inhibitor and its efficacy as a tyrosine kinase was assessed in chronic myeloid leukemia [46].
Negative_regulation (inhibitor) of PDGFR associated with leukemia
8) Confidence 0.27 Published 2009 Journal World J Surg Oncol Section Body Doc Link PMC2749031 Disease Relevance 1.34 Pain Relevance 0.13
Since both STI571 and the more specific PDGF aptamers exerted similar effects in KAT-4 tumors on regulation of IFP and Taxol treatment efficiency [11], the observed effects of STI571 are likely to be mediated by inhibition of PDGFR.
Negative_regulation (inhibition) of PDGFR associated with cancer and taxol
9) Confidence 0.21 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2781164 Disease Relevance 0.43 Pain Relevance 0.27
In this study, we investigated whether the combination of PDGFR and VEGFR inhibitors could further reduce the IFP of KAT-4 human carcinoma tumors.
Negative_regulation (inhibitors) of PDGFR associated with cancer and carcinoma
10) Confidence 0.21 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2781164 Disease Relevance 0.78 Pain Relevance 0.03
GISTs may show poor response to chemotherapy, but not to imatinib mesylate, also known as STI571 [11,45] which was found to act as a powerful selective inhibitor of tyrosine kinases of PDGFR and of c-kit receptor.
Negative_regulation (inhibitor) of PDGFR
11) Confidence 0.19 Published 2009 Journal World J Surg Oncol Section Body Doc Link PMC2749031 Disease Relevance 1.36 Pain Relevance 0.14
We therefore used a modest concentration of PTK/ZK to avoid inhibition of PDGFR [13].
Negative_regulation (inhibition) of PDGFR
12) Confidence 0.19 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2781164 Disease Relevance 0.24 Pain Relevance 0
Specifically, it has been shown to inhibit KIT, PDGFR, FMS-like tyrosine kinase 3 and VEGF.
Negative_regulation (inhibit) of PDGFR associated with fibromyalgia
13) Confidence 0.19 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503651 Disease Relevance 0.63 Pain Relevance 0
Other new agents are PKC 412 (inhibitor of protein kinase C, KIT, PDGFR, and VEGF), BMS-354825 (tyrosine kinase inhibitor of KIT, PDGFR, abl and src), oblimerson sodium (an antisense oligonucleotide inhibiting BCL-2), and CCI 779 (a rapamycin analogue inhibitor of the protein kinase mammalian target of rapamycin).
Negative_regulation (inhibitor) of PDGFR associated with kinase c
14) Confidence 0.19 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503651 Disease Relevance 0.54 Pain Relevance 0.05
Other new agents are PKC 412 (inhibitor of protein kinase C, KIT, PDGFR, and VEGF), BMS-354825 (tyrosine kinase inhibitor of KIT, PDGFR, abl and src), oblimerson sodium (an antisense oligonucleotide inhibiting BCL-2), and CCI 779 (a rapamycin analogue inhibitor of the protein kinase mammalian target of rapamycin).
Negative_regulation (inhibitor) of PDGFR associated with kinase c
15) Confidence 0.19 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503651 Disease Relevance 0.55 Pain Relevance 0.05
This drug inhibits the KIT and PDGFR?
Negative_regulation (inhibits) of PDGFR
16) Confidence 0.17 Published 2009 Journal World J Surg Oncol Section Body Doc Link PMC2749031 Disease Relevance 0.60 Pain Relevance 0.06
It was speculated, that imatinib negatively affects the formation and resorption of bone by inhibiting the PDGFR (Berman et al 2006).
Negative_regulation (inhibiting) of PDGFR
17) Confidence 0.16 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503652 Disease Relevance 0.70 Pain Relevance 0
Imatinib mesylate is a tyrosine kinase inhibitor with activity against activated PDGFR, and has significant activity against DFSP.
Negative_regulation (inhibitor) of PDGFR
18) Confidence 0.06 Published 2007 Journal Biologics : Targets & Therapy Section Abstract Doc Link PMC2721290 Disease Relevance 0.49 Pain Relevance 0
In a seminal paper phosphorylation level of PDGFR?
Negative_regulation (level) of PDGFR
19) Confidence 0.06 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721290 Disease Relevance 0.24 Pain Relevance 0
Vogelzang et al. recently reviewed new agents that under evaluation for the treatment of MM, including EGFR, PDGFR, VEGF and HGF inhibitors, inhibitors of mTOR, a downstream molecule of the PI3K/AKT pathway, and inhibitors of the proteasome/ubiquitin pathway (Vogelzang, 2005).
Negative_regulation (inhibitors) of PDGFR in HGF associated with lung cancer
20) Confidence 0.05 Published 2007 Journal Biomarker Insights Section Body Doc Link PMC2717840 Disease Relevance 1.25 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox